$24.99
2.61% yesterday
Nasdaq, Apr 25, 10:00 pm CET
ISIN
US92686J1060
Symbol
VKTX
Sector
Industry

Viking Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation

Viking Therapeutics, Inc. Classifications & Recommendation:

Buy
89%
Hold
11%

Viking Therapeutics, Inc. Price Target

Target Price $89.50
Price $24.99
Potential
Number of Estimates 18
18 Analysts have issued a price target Viking Therapeutics, Inc. 2026 . The average Viking Therapeutics, Inc. target price is $89.50. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 18 analysts: 16 Analysts recommend Viking Therapeutics, Inc. to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Viking Therapeutics, Inc. stock has an average upside potential 2026 of . Most analysts recommend the Viking Therapeutics, Inc. stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -1.01 -1.82
10.99% 80.20%
P/E negative
EV/Sales 1,251.35

18 Analysts have issued a Viking Therapeutics, Inc. forecast for earnings per share. The average Viking Therapeutics, Inc. EPS is

$-1.82
Unlock
. This is
58.26% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-1.30 13.04%
Unlock
, the lowest is
$-2.40 108.70%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-1.01 10.99%
2025
$-1.82 80.20%
Unlock
2026
$-2.44 34.07%
Unlock
2027
$-2.94 20.49%
Unlock
2028
$-2.54 13.61%
Unlock
2029
$0.00 100.00%
Unlock

P/E ratio

Current -21.70 68.70%
2025
-13.71 36.82%
Unlock
2026
-10.22 25.46%
Unlock
2027
-8.49 16.93%
Unlock
2028
-9.83 15.78%
Unlock

Current Viking Therapeutics, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked Apr 24 2025
Morgan Stanley
Locked
Locked
Locked Apr 24 2025
HC Wainwright & Co.
Locked
Locked
Locked Apr 17 2025
Goldman Sachs
Locked
Locked
Locked Apr 08 2025
HC Wainwright & Co.
Locked
Locked
Locked Mar 26 2025
HC Wainwright & Co.
Locked
Locked
Locked Mar 11 2025
Scotiabank
Locked
Locked
Locked Feb 13 2025
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
Apr 24 2025
Locked
Morgan Stanley:
Locked
Locked
Apr 24 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Apr 17 2025
Locked
Goldman Sachs:
Locked
Locked
Apr 08 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 26 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 11 2025
Locked
Scotiabank:
Locked
Locked
Feb 13 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today